To read the full story, subscribe or sign in.

Novosom In-Licenses Antisense CD40 Inhibitors from Isis Pharma

Aug. 27, 2008

Novosom AG in-licensed from Isis Pharmaceuticals Inc. the rights to antisense inhibitors that target CD40 mRNA for several indications, including Crohn's disease, rheumatoid arthritis and organ transplant rejection. (BioWorld International)

BioWorld Asia

Today's news in brief

BioWorld

BioWorld briefs for June 24, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...